|Videos|October 20, 2022
Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial
Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.
Advertisement
Episodes in this series
Advertisement
Related to this article
An IDMC recommended continuing a phase 2 minimal residual disease study of IMNN-001 without modification following a favorable safety review.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Long-term data from the L-MOCA trial showed encouraging OS outcomes with olaparib maintenance in Asian patients with platinum-sensitive, relapsed ovarian cancer.
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.
Toon Van Gorp, MD, PhD, discusses NAPISTAR 1-01 trial design, safety findings, and efficacy across dose levels of TUB-040 in ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Plinabulin Plus Docetaxel in Post-ICI Non-Squamous NSCLC
2
Breast Cancer Experts Highlight Abstracts to Watch at ESMO 2026
3
FDA Approves Denosumab Biosimilar for Skeletal-Related Events, GCTB, and Hypercalcemia of Malignancy
4
Navigating DLL3-Targeting T-Cell Engagers and the Evolving Small Cell Lung Cancer Treatment Landscape
5